Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Go Global Or Stay Home? Geopolitics, Funding Crunch May Force China Biotechs To Choose

Executive Summary

Having been used to navigating the Pacific with few obstacles, biotech companies taking advantage of Chinese resources and US innovation now face ballooning tensions between the two countries, which along with narrowing funding channels will increasingly force them to decide where to place their bets in the world’s largest economies.

You may also be interested in...



Location, Location, Location: Will Sorrento’s China-Only NSCLC Data Fly With US FDA?

Sorrento plans to meet with the US FDA regarding abivertinib, but the agency’s tough stance on drug approvals based on single-country studies could thwart the company’s efforts.

US Toning Down China CDMO Tension But New Restrictions Emerge

The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy. 

China HPV Demand Shaping Merck But Competitors Catching Up

Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel